PATENT CLAIM ANALYSIS

Application Number: 16017303
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "364000"]

Abstract:
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Claim (Index 3):
The method of  claim 1 , wherein the administering step comprises administering the hydrochloride salt of the compound to the mammalian subject.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 94.0
- Lexical Diversity: 1.24
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16017345', '14261175', '12747253', '12894783', '15287381']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7513888477922765
- 35 USC 102 Novelty (BERT): 0.6841382174378191
- Combined Prediction Score: 0.7446637847568309
- Mean Citation Score: 362.980328
- Max Citation Score: 738.8680400000003
- Similarity Product: 659.2141846974947

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test